Pfizer’s EGFR TKI Vizimpro may now be prescribed at general hospitals.

According to industry sources, Pfizer Korea’s Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib) passed the Drug Committees (DCs) of four of the Big-5s - Samsung Medical Center (SMC), Seoul National University Hospital (SNUH), Seoul St. Mary’s Hospital, Asan Medical Center (AMC) – and many other major medical institutions including the National Cancer Center, Seoul National University Bundang Hospital, Pusan National University Hospital, Chungbuk National University Hospital, and Chungnam National University Hospital, etc.

Vizimpro, which was listed for reimbursemen